BMY vs. ZTS, PFE, ABBV, MRK, JNJ, GSK, REGN, VRTX, SNY, and TAK
Should you be buying Bristol-Myers Squibb stock or one of its competitors? The main competitors of Bristol-Myers Squibb include Zoetis (ZTS), Pfizer (PFE), AbbVie (ABBV), Merck & Co., Inc. (MRK), Johnson & Johnson (JNJ), GSK (GSK), Regeneron Pharmaceuticals (REGN), Vertex Pharmaceuticals (VRTX), Sanofi (SNY), and Takeda Pharmaceutical (TAK). These companies are all part of the "pharmaceutical preparations" industry.
Zoetis (NYSE:ZTS) and Bristol-Myers Squibb (NYSE:BMY) are both large-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, community ranking, dividends, valuation, institutional ownership, earnings, media sentiment, profitability and risk.
Bristol-Myers Squibb has higher revenue and earnings than Zoetis. Bristol-Myers Squibb is trading at a lower price-to-earnings ratio than Zoetis, indicating that it is currently the more affordable of the two stocks.
Zoetis has a beta of 0.85, suggesting that its share price is 15% less volatile than the S&P 500. Comparatively, Bristol-Myers Squibb has a beta of 0.39, suggesting that its share price is 61% less volatile than the S&P 500.
Zoetis pays an annual dividend of $1.73 per share and has a dividend yield of 1.1%. Bristol-Myers Squibb pays an annual dividend of $2.40 per share and has a dividend yield of 5.4%. Zoetis pays out 34.1% of its earnings in the form of a dividend. Bristol-Myers Squibb pays out -77.4% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Zoetis has increased its dividend for 12 consecutive years. Bristol-Myers Squibb is clearly the better dividend stock, given its higher yield and lower payout ratio.
92.8% of Zoetis shares are held by institutional investors. Comparatively, 76.4% of Bristol-Myers Squibb shares are held by institutional investors. 0.2% of Zoetis shares are held by company insiders. Comparatively, 0.1% of Bristol-Myers Squibb shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
In the previous week, Bristol-Myers Squibb had 51 more articles in the media than Zoetis. MarketBeat recorded 85 mentions for Bristol-Myers Squibb and 34 mentions for Zoetis. Bristol-Myers Squibb's average media sentiment score of 0.34 beat Zoetis' score of 0.08 indicating that Zoetis is being referred to more favorably in the media.
Zoetis presently has a consensus price target of $216.13, suggesting a potential upside of 36.24%. Bristol-Myers Squibb has a consensus price target of $60.00, suggesting a potential upside of 36.24%. Given Zoetis' higher possible upside, analysts plainly believe Bristol-Myers Squibb is more favorable than Zoetis.
Zoetis has a net margin of 27.43% compared to Zoetis' net margin of -13.50%. Bristol-Myers Squibb's return on equity of 51.25% beat Zoetis' return on equity.
Bristol-Myers Squibb received 182 more outperform votes than Zoetis when rated by MarketBeat users. However, 77.78% of users gave Zoetis an outperform vote while only 66.87% of users gave Bristol-Myers Squibb an outperform vote.
Summary
Zoetis beats Bristol-Myers Squibb on 14 of the 21 factors compared between the two stocks.
Get Bristol-Myers Squibb News Delivered to You Automatically
Sign up to receive the latest news and ratings for BMY and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BMY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Bristol-Myers Squibb Competitors List
Related Companies and Tools
